뉴트리밴드(NTRB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.30 (+3.45%), 시가총액 $0.04B, 52주 범위 $3.46 ~ $10.72.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
뉴트리밴드의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
뉴트리밴드의 현재 주가는 $3.30 (+3.45%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
뉴트리밴드의 시가총액은 약 $0.04B입니다.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal s